Vera's approval is done. The launch is the test

The technology

Atacicept, now sold as Trutakna, is a fusion protein that traps two immune signals, BAFF and APRIL. Both help B cells make the abnormal antibodies, called galactose-deficient IgA1, that damage the kidney in IgA nephropathy. Vera says Trutakna is the first and only BAFF and APRIL inhibitor approved for IgAN. It is given as a 150 mg weekly injection with an at-home autoinjector.

The idea is to act upstream of the kidney damage rather than on its downstream effects. In ORIGIN 3, the phase 3 trial, proteinuria fell 46% from baseline and 42% against placebo at 36 weeks, and the Gd-IgA1 antibody fell 68%. The final analysis, announced September 15, reported an annualized eGFR slope of -0.6 on atacicept versus -5.6 on placebo through 104 weeks.

Vera also has a second-generation molecule, VT-109, which it licensed from Stanford and which is still preclinical.

The odds

The regulatory question is mostly settled. The FDA granted accelerated approval on July 7, and the BIO/Informa/QLS base rates showed that 93.6% of rare disease filings reach approval (90.6% across all indications). The remaining regulatory step is conversion to full approval, which Vera plans to seek through a supplemental application in the fourth quarter. The September data covered 428 patients and showed 11 progression events on Trutakna versus 38 on placebo, with no dialysis, transplant or death on the drug, so the evidence for conversion is strong on its face.

The harder question is commercial. Trutakna is the sixth drug approved for IgAN. Otsuka's Voyxact is already on the market at a lower list price, and Vertex's povetacicept has an FDA decision date of Nov. 30. Base rates say little about this. Vera's read on launch is early: it reported more than 350 patient start forms in the first 10 weeks.

The money

Vera is a pre-revenue company with a large cost base. It held $499.2 million at June 30, down from $714.6 million at the end of 2025, after a second-quarter net loss of $109.5 million. Operating cash use was $206.8 million for the first half. The company can draw up to $425 million more from a debt facility, subject to conditions, and has said it expects to fund operations through launch.

General and administrative expense of $52.4 million in the second quarter was more than twice the prior-year level, as the commercial team was built. Product revenue should begin to appear in the third-quarter report, which Vera has not yet scheduled. The list price is $425,000 a year.

The risks

Four risks matter. First, the approval is accelerated: the FDA has said it has not established that Trutakna slows long-term kidney decline, and conversion needs a successful filing. Second, competition. Otsuka plans a full-approval filing for Voyxact in 2026, Novartis already sells Fabhalta and Vanrafia, and Vertex has filed a rival BAFF and APRIL drug. Third, safety. Infections occurred in 32% of treated patients versus 28% on placebo, and injection site reactions in 19% versus 2%, and the label carries infection and vaccine warnings. Fourth, funding. The company has burned about $34 million a month in 2026, and further financing is possible if uptake is slow.

Our read

Vera has done what a single-asset biotech needs to do: it got the drug approved, and then it reported randomized evidence on kidney function that supports the conversion filing. The science looks strong, and the September data are the best so far in a market where Otsuka and Novartis have both claimed kidney-function benefits of their own.

What is left is execution. The company must persuade nephrologists to add a weekly self-injection at a price above its closest competitor, and must do it while spending several hundred million dollars a year. Early start forms are encouraging but not revenue. The next checkpoints are the supplemental filing, Vertex's decision and the first reported Trutakna sales.